Healthcare / Medical DistributionTel Aviv
$91.60
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $99.8M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$468M
P/E
91.6x
↑EV/EBITDA
423.2x
↑ROE
1.2%
↑Gross Margin
7.6%
↓Debt/Equity
0.51
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.2%
FCF CAGR
—
FCF margin
-3.5%
FCF / Net income
-15.38x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.81B · net income $4.1M · FCF $-63.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.81B | $1.81B | $2.02B | $1.64B | $1.51B |
| Net Income | $4.1M | $4.1M | $39.5M | $-42.0M | $47.5M |
| EBITDA | $110.7M | $110.7M | $149.4M | $130.1M | $138.5M |
| EPS | — | — | 0.08 | -0.08 | 0.09 |
| Gross Margin | 7.6% | 7.6% | 8.9% | 10.3% | 11.6% |
| Operating Margin | 1.5% | 1.5% | 3.5% | 3.1% | 5.2% |
| Net Margin | 0.2% | 0.2% | 2.0% | -2.6% | 3.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.51 | 0.51 | 0.54 | 0.58 | 0.49 |
| Current Ratio | 0.94 | 0.94 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-63.3M | $-63.3M | $99.8M | $129.1M | $63.2M |
| Returns | |||||
| ROE | 1.2% | 1.2% | 10.7% | -11.3% | 10.9% |
| Valuation | |||||
| P/E | 91.60 | 91.60 | 2429.87 | — | 2892.39 |
| EV/EBITDA | 423.25 | 423.25 | 639.32 | 560.49 | 991.10 |
| P/B | 131.14 | 131.14 | 259.40 | 196.61 | 315.01 |
| Growth & Yield | |||||
| Revenue Growth | -10.7% | -10.7% | 23.0% | 9.0% | — |
| EPS Growth | — | — | 193.9% | -189.1% | — |
| Dividend Yield | 4.3% | 4.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-40.1%
Start / end P/E
n/dx → n/dx
EPS bridge
0.08 → n/d
Residual
-44.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.